These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7302264

  • 1. OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro.
    Smith JB, Jubiz W.
    Prostaglandins; 1981 Sep; 22(3):353-63. PubMed ID: 7302264
    [Abstract] [Full Text] [Related]

  • 2. Arachidonic acid induced platelet aggregation and thromboxane formation is inhibited by OKY-1581.
    Uotila P, Matintalo M, Dahl ML.
    Prostaglandins Leukot Med; 1983 Nov; 12(3):299-303. PubMed ID: 6419237
    [Abstract] [Full Text] [Related]

  • 3. Effect of OKY-046, a selective thromboxane inhibitor, on prostaglandin production and function of pregnant rat uteri and platelets.
    Ghodgaonkar RB, Dubin NH.
    Prostaglandins Leukot Med; 1987 Jan; 26(1):33-46. PubMed ID: 3468521
    [Abstract] [Full Text] [Related]

  • 4. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y, Hattori R, Takatsu Y, Nakajima H, Wakabayashi A, Kawai C, Kayama N, Hiraku S, Inagawa T, Tsubojima M.
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [Abstract] [Full Text] [Related]

  • 5. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
    Uyama O, Nagatsuka K, Nakabayashi S, Isaka Y, Yoneda S, Kimura K, Abe H.
    Stroke; 1985 Oct; 16(2):241-4. PubMed ID: 3883580
    [Abstract] [Full Text] [Related]

  • 6. Lithium stimulates thromboxane B2 formation in human platelets.
    Imandt L, Tijhuis D, Wessels H, Haanen C, van den Berg R, Thomas C.
    Prostaglandins Med; 1981 Nov; 7(5):421-9. PubMed ID: 6798588
    [Abstract] [Full Text] [Related]

  • 7. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats.
    Gomi T, Ikeda T, Ishimitsu T, Uehara Y.
    Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692
    [Abstract] [Full Text] [Related]

  • 8. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise.
    Shikano M, Ito T, Ogawa K, Satake T.
    Jpn Heart J; 1987 Sep; 28(5):663-74. PubMed ID: 3323562
    [Abstract] [Full Text] [Related]

  • 9. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
    Kuzuya T, Hoshida S, Yamagishi M, Ohmori M, Inoue M, Kamada T, Tada M.
    Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of platelet aggregation and thromboxane production by pinacidil.
    Goodman RP, Little DM, Wright JT.
    Prostaglandins Leukot Med; 1985 Aug; 19(2):115-22. PubMed ID: 3931098
    [Abstract] [Full Text] [Related]

  • 11. A new approach to antithrombotic therapy--evaluation of combined therapy of thromboxane synthetase inhibitor and very low dose of aspirin.
    Nagatsuka K, Uyama O, Nakabayashi S, Yoneda S, Kimura K, Kamada T.
    Stroke; 1985 Aug; 16(5):806-9. PubMed ID: 3931302
    [Abstract] [Full Text] [Related]

  • 12. Effect of cetiedil on platelet aggregation and thromboxane synthesis.
    Yamaguchi A, Asakura T, Tanoue K, Yamazaki H.
    Thromb Res; 1985 Feb 01; 37(3):391-400. PubMed ID: 2986312
    [Abstract] [Full Text] [Related]

  • 13. A comparative study of collagen induced thromboxane release from platelets of different species: implications for human atherosclerosis models.
    Leach CM, Thorburn GD.
    Prostaglandins; 1982 Jul 01; 24(1):47-59. PubMed ID: 7122912
    [Abstract] [Full Text] [Related]

  • 14. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord].
    Morimoto K, Ikata T, Tounai T.
    Nihon Seikeigeka Gakkai Zasshi; 1990 Jan 01; 64(1):82-8. PubMed ID: 2319197
    [Abstract] [Full Text] [Related]

  • 15. Effect of intravenous infusion of OKY-1581 (sodium-(E)-3-[4-(3-pyridylmethyl)phenyl] -2-methylacrylate) on circulatory thromboxane A2 and prostacyclin levels in anaesthetized baboon.
    Roy AC, Adaikan PG, Karim SM.
    Prostaglandins Med; 1981 Sep 01; 7(3):253-9. PubMed ID: 7029585
    [No Abstract] [Full Text] [Related]

  • 16. Nicergoline, an anti-aggregating agent which inhibits release of arachidonic acid from human platelet phospholipids.
    Lagarde M, Guichardant M, Ghazi I, Dechavanne M.
    Prostaglandins; 1980 Apr 01; 19(4):551-7. PubMed ID: 7384555
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans.
    Ito T, Ogawa K, Sakai K, Watanabe J, Satake T, Kayama N, Hiraku S, Naito J.
    Adv Prostaglandin Thromboxane Leukot Res; 1983 Apr 01; 11():245-51. PubMed ID: 6221531
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets.
    Uotila P, Matintalo M.
    Prostaglandins Leukot Med; 1984 Apr 01; 14(1):41-6. PubMed ID: 6427791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.